ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Rheumatology · J Rheumatol · 2026-11-01

Secondary analysis of four phase III trials and open-label extensions in axSpA (n=586) and PsA (n=1112): with bimekizumab, mean EQ VAS improved 20.2–21.3 (axSpA) and 17.1–17.3 points (PsA) by year 3; most had meaningful work-impairment improvement. Observed cases, no comparator.

Secondary analysisn = 1,698
Nikiphorou et al. Effect of Bimekizumab Treatment on Health Status, Work Productivity, and Productivity Costs Through 3 Years in Axial Spondyloarthritis and Psoriatic Arthritis
Rheumatology · Ann Rheum Dis · 2026-08-07

In 670 biologic-naïve adults with active psoriatic arthritis, oral deucravacitinib 6 mg once daily beat placebo for ACR20 at week 16 (54.2% vs 34.1%, P<.001), with responses increased at week 52 and low serious adverse events (1.8% vs 2.4%).

RCTn = 670
van der Heijde et al. Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: 52-week results from the randomised, double-blind, placebo-controlled phase 3 POETYK PsA-1 trial
Rheumatology · J Rheumatol · 2026-08-01

Systematic review of 41 studies (19 RCTs, 6171 patients, meta-analysed) in axial spondyloarthritis on biologics or tsDMARDs: pooled proportion reaching ASDAS inactive disease was 0.24 at 12–24 weeks; odds of inactive disease vs low disease activity were 0.30.

Meta-analysisn = 6,171
Doumeth et al. Achieving Axial Spondyloarthritis Disease Activity Score Inactive Disease Status in Axial Spondyloarthritis in Clinical Trials: A Systematic Review and Metaanalysis
Rheumatology · Rheumatology (Oxford) · 2026-06-30

Exploratory secondary analysis of the GOLMePsA trial: whole-body MRI in 31 people with early, treatment-naïve PsA showed widespread low-intensity peripheral inflammation, improving by weeks 24 and 36 with no difference between MTX plus golimumab and MTX alone.

Secondary analysisn = 31
De Marco et al. Whole body-MRI identifies widespread, low intensity inflammation in peripheral joints, and axial involvement in a third of patients with early, treatment-naïve, active PsA: data from the GOLMePsA clinical trial
Rheumatology · Lancet Rheumatol · 2026-06-29

In 502 adults with moderate-to-severe plaque psoriasis, biosimilar BAT2306 was equivalent to reference secukinumab for percentage PASI change at week 8 (difference 1·549) and week 12 (−0·349), within all regulatory margins; safety and immunogenicity were comparable.

RCTn = 502
Chen et al. Secukinumab biosimilar BAT2306 versus reference secukinumab in patients with moderate-to-severe plaque psoriasis: a multicentre, double-blind, randomised, active-controlled, phase 3 trial
Rheumatology · Ann Rheum Dis · 2026-06-25

Post hoc analysis of a phase 3 ixekizumab vs placebo trial in nonradiographic axial spondyloarthritis: patients meeting established or proposed MRI sacroiliac joint definitions had similar baseline features and week-16 outcomes; proposed did not outperform established.

Secondary analysis
Baraliakos et al. Comparison of the established ASAS definition and preliminary proposed data-driven cut-offs for inflammatory and structural MRI lesions in the sacroiliac joints for eligibility of patients with nonradiographic axial spondyloarthritis in clinical trials
Rheumatology · Rheumatology (Oxford) · 2026-06-03

Meta-analysis of 5 observational studies (2300 patients) with psoriatic arthritis after TNF inhibitor failure: cycling to another TNFi versus swapping mechanism showed no significant difference in lack of response (RR 0.99), retention or adverse events.

Meta-analysisn = 2,300
Tomo et al. Cycling versus swapping strategies for treatment of psoriatic arthritis after primary tumour necrosis factor inhibitors failure: a systematic review and meta-analysis
Rheumatology · RMD Open · 2026-05-13

Pooled open-label extension of 2 bimekizumab trials in axial spondyloarthritis: of 494 entering the extension, 425 completed week 164, with mean improvements from baseline in spinal pain (−4.3), BASFI (−2.9), fatigue and SF-36 PCS (+12.3); no comparator.

RCTn = 586
Navarro-Compán et al. Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension
Rheumatology · Arthritis Rheumatol · 2026-05-11

Phase 2a trial in 91 adults with psoriatic arthritis after TNF inhibitor failure: guselkumab plus golimumab did not significantly improve week-24 minimal disease activity vs guselkumab alone (29% vs 22%; OR 1.4; P=0.557). Secondary ACR50 was 44% vs 22%.

RCTn = 91
Scher et al. Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double-Blind, Proof-of-Concept Study

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.